Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 1997

View Archived Issues

Abbott's newest dopaminergic compounds described in patent literature

5-HT4 antagonists disclosed by Taisho

Cephems in development at Meiji Seika

Cell migration inhibitors from Teijin

Japanese researchers develop new HIV protease inhibitors

Magainin analogues reported by Scripps

Pollakiuria treatment described by SS Pharm.

Tanabe Seiyaku discloses novel antinephritic compounds

Egis develops 5-LO inhibitors

Antitumor prodrugs for ADEPT from Pharmachemie

BTG describes immunosuppressive antibodies

BASF discloses antithrombotic from ticks

Lilly/Novo Nordisk discover candidate for IBS

Clinical trial data reported for meningitis vaccine

Another approval for first-line Abelcet

Hemosol discloses novel cellular immunotherapeutic procedure

Genzyme acquires PharmaGenics and forms new division

LifeTECH and Pall announce collaboration

Abgenix reports significant advance in human antibody technology

First Corlopam Renal Program study completed

Access/Dow collaborate on contrast agents and radiopharmaceuticals

Sugen's TK antagonist enters phase II

Antiobesity agent from Neurogen/Pfizer advances to multiple-dose trials

Whole-body hyperthermia therapy enters clinic for new indication

FDA approval for Ferring antifertility Rx

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...